A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Study will evaluate the efficacy of a new compound versus placebo in the treatment of
patients with schizophrenia (diagnosed by DSM-IV criteria) as measured by reductions from
baseline on the total score of the Brief Psychiatric Rating Scale (BPRS) as extracted from
the Positive and Negative Syndrome Scale (PANSS).

Inclusion Criteria:

- Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV

- The patient must agree to a voluntary hospitalization duration of 31 days minimum at
the start of the treatment

- If female, must not be pregnant, or must be incapable of conceiving or be taking
steps to prevent conception

Exclusion Criteria:

- The patient has used an investigational drug within the past 30 days

- The patient has participated in a previous study of this compound